The anxiolytic-like effect of an essential oil derived from Spiranthera odoratissima A. St. Hil. leaves and its major component, β-caryophyllene, in male mice

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 38, Issue 2, 2012, Pages 276-284

  Galdino, Pablinny Moreira ^a,b   Nascimento, Marcus Vinícius Mariano ^a   Florentino, Iziara Ferreira ^a   Lino, Roberta Campos ^a   Fajemiroye, James Oluwagbamigbe ^a   Chaibub, Beatriz Abdallah ^a   de Paula, José Realino ^a   de Lima, Thereza Christina Monteiro ^b   Costa, Elson Alves ^a  

^a FEDERAL UNIVERSITY OF GOIÁS   (Brazil)

^b FEDERAL UNIVERSITY OF SANTA CATARINA   (Brazil)

Author keywords

caryophyllene; Anxiolytic like effect; Flumazenil; NAN 190; Spiranthera odoratissima

Indexed keywords

1 (2 METHOXYPHENYL) 4 (4 PHTHALIMIDOBUTYL)PIPERAZINE; BENZODIAZEPINE RECEPTOR; CARYOPHYLLENE; DIAZEPAM; ESSENTIAL OIL; FLUMAZENIL; SEROTONIN 1A RECEPTOR;

ALIENATION; ANALGESIA; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG MECHANISM; LATENT PERIOD; LIGHT DARK CYCLE; MALE; MAZE TEST; MEDICINAL PLANT; MOBILIZATION; MOTOR PERFORMANCE; MOUSE; NONHUMAN; OPEN FIELD BEHAVIOR; OPEN FIELD TEST; ROTAROD TEST; SLEEP TIME; SPIRANTHERA ODORATISSIMA; TRANQUILIZING ACTIVITY; WRITHING TEST;

ANIMALS; ANTI-ANXIETY AGENTS; ANXIETY; BEHAVIOR, ANIMAL; MALE; MICE; MOTOR ACTIVITY; OILS, VOLATILE; PENTOBARBITAL; PLANT EXTRACTS; ROTAROD PERFORMANCE TEST; RUTACEAE; SESQUITERPENES; SLEEP;

EID: 84862857179     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2012.04.012     Document Type: Article

References (71)

1. Almeida Filho N., Mari J.J., Coutinho E., França J.F., Fernandes J.G., Andreoli S.B., et al. Estudo multicêntrico de morbidade psiquiátrica em áreas urbanas brasileiras (Brasília, São Paulo, Porto Alegre). Revista ABP-APAL 1992, 14:93-104.
2. Almeida S.P., Proença C.E.B., Sano S.M., Ribeiro J.F. Cerrado: Espécies Vegetais úteis 1998, EMBRAPA-CPAC, Planaltina.
3. Angrini M., Leslie J.C., Shephard R.A. Effects of propranolol, buspirone, pCPA, reserpine, and chlordiazepoxide on open-field behavior. Pharmacol Biochem Behav 1998, 59:387-397.
4. Archer J. Tests for emotionality in rats and mice: a review. Anim Behav 1973, 21:205-235.
5. Bambico F.R., Katz N., Debonnel G., Gobbi G. Cannabinoids elicit antidepressant-like behavior and activate serotonergic neurons through the medial prefrontal cortex. J Neurosci 2007, 27:11700-11711.
6. Belzung C., Griebel G. Measuring normal and pathological anxiety-like behavior in mice: a review. Behav Brain Res 2001, 125:141-149.
7. Bertoglio L., Carobrez A.P. Ethological and temporal analyses of anxiety-like behavior: the elevated plus-maze model 20years on. Neurosci Behav Rev 2005, 29:1193-1205.
8. Blier P., Lista A., De M.C. Differential properties of pre- and postsynaptic 5- hydroxytryptamine1A receptors in the dorsal raphe and hippocampus: II. Effect of pertussis and cholera toxins. J Pharmacol Exp Ther 1993, 265:16-23.
9. Bourin M., Petit-Demoulière B., Dhonnchadha B.N., Hascöet M. Animal models of anxiety in mice. Fundam Clin Pharmacol 2007, 21:567-574.
10. Carlini E.A., Burgos V. Screening farmacológico de ansiolíticos: metodologia laboratorial e comparação entre diazepam e clorobenzepam. Rev Assoc Bras Psiquiatr 1979, 1:25-31.
11. Carvalho-Freitas M.I.R., Costa M. Anxiolytic and sedative effects of extracts and essential oil from Citrus aurantium L. Biol Pharm Bull 2002, 25:1629-1633.
12. Celedonio, Natália Rocha, 2008. Estudo do mecanismo de ação antinociceptivo e antiedematogênico do óleo essencial de Croton argyrophylloides e seus constituintes: alfa-pineno e trans-cariofileno. [Dissertação de Mestrado - Universidade Estadual do Ceará]. 141 p.
13. Chaibub B.A., Paula J.R. Análise da composição química do óleo essencial e avaliação da atividade antimicrobiana do óleo essencial e extrato etanólico bruto de Spiranthera odoratissima A. St. Hil. Anais do VI Congresso de Pesquisa, Ensino e Extensão 2009, 1891-1901.
14. Chang H.J., Kim H.J., Chun H.S. Quantitative structure-activity relationship (QSAR) for neuroprotective activity of terpenoids. Life Sci 2007, 80:835-841.
15. Clark G., Koester A.G., Pearson D.W. Exploratory behavior in chronic disulfoton poisoning in mice. Psychopharmacology 1971, 20:169-171.
16. Crawley J.N. Exploratory behavior models of anxiety in mice. Neurosci Behav Rev 1985, 9:37-44.
17. Crawley J.N., Goodwin F.K. Preliminary report of a simple animal behavior model for the anxiolytic effects of benzodiazepines. Pharmacol Biochem Behav 1980, 13:167-170.
18. Dunham N.W., Miya T.S. A note on a simple apparatus for detecting neurological deficit in rats and mice. J Am Pharm Assoc 1957, 46:208-210.
19. Faustino T.T., Almeida R.B., Andreatini R. Plantas medicinais no tratamento do transtorno de ansiedade generalizada: uma revisão dos estudos clínicos controlados. Rev Bras Psiquiatr 2010, 32:429-436.
20. Fernandes E.S., Passos G.F., Medeiros R., Cunha F.M., Ferreira J., Campos M.M., et al. Anti-inflammatory effects of compounds alpha-humulene and (-)-trans-caryophyllene isolated from the essential oil of Cordia verbenacea. Eur J Pharmacol 2007, 569:228-236.
21. File S.E. Recent developments in anxiety, stress, and depression. Pharmacol Biochem Behav 1996, 54:3-12.
22. Foong J.P., Bornstein J.C. 5-HT antagonists NAN-190 and SB 269970 block alpha2-adrenoceptors in the guinea pig. Neuroreport 2009, 20:325-330.
23. Galindo L.A., Pultrini A.M., Costa M. Biological effects of Ocimum gratissimum L. are due to synergic action among multiple compounds present in essential oil. J Nat Med 2010, 64:436-441.
24. Gammans R.E., Stringfellow J.C., Hvidzos A.J., Seidehamel R.J., Cohn J.B., Wilcox C.S., et al. Use of buspirone in patients with generalised anxiety disorder and coexisting depressive symptoms: a meta-analysis of eight randomised controlled trials. Neuropsychobiology 1992, 25:193-201.
25. Gertsch J., Leonti M., Raduner S., Racz I., Chen J.J., Xie X.Q., et al. Beta-caryophyllene is a dietary cannabinoid. Proc Natl Acad Sci 2008, 105:9099-9104.
26. Ghelardini C., Galeotti N., Mannelli L.D.C., Mazzanti G., Bartolini A. Local anaesthesic activity of β-caryophyllene. Farmaco 2001, 56:387-389.
27. Goa K.L., Ward A. Buspirone: a preliminary review of its pharmacological properties and therapeutic efficacy as an anxiolytic. Drugs 1986, 32:114-129.
28. Gonzalez-Trujano M.E., Carrera D., Ventura-Martinez R., Cedillo-Portugal E., Navarrete A. Neuropharmacological profile of an ethanol extract of Ruta chalepensis L. in mice. J Ethnopharmacol 2006, 106:129-135.
29. Graeff F.G., Zangrossi H. Animal models of anxiety disorders. Biological psychiatry 2002, 96-103. John Wiley & Sons Ltd., New Jersey. H. D'Haenen, J.A. den Boer, P. Willner (Eds.).
30. Graeff F.G., Guimaraes F.S., De Andrade T.G., Deakin J.F. Role of 5-HT in stress, anxiety, and depression. Pharmacol Biochem Behav 1996, 54:129-141.
31. Haj-Dahmane S., Shen R.Y. Modulation of the serotonin system by endocannabinoid signaling. Neuropharmacology 2011, 61:414-420.
32. Harada K., Aota M., Inoue T., Matsuda R., Mihara T., Yamaji T., et al. Anxiolytic activity of a novel potent serotonin 5-HT2C receptor antagonist FR260010: a comparison with diazepam and buspirone. Eur J Pharmacol 2006, 553:171-184.
33. Huo F.Q., Huang F.S., Lv B.C., Chen T., Feng J., Qu C.L., et al. Activation of serotonin 1A receptors in ventrolateral orbital cortex depresses persistent nociception: a presynaptic inhibition mechanism. Neurochem Int 2010, 57:749-755.
34. Kessler R.C., Greenberg P.E. The economic burden of anxiety and stress disorders. Neuropsychopharmacology: the fifth generation of progress 2002, 981-992. Lippincott Williams & Wilkins, Philadelphia. K.L. Davis, D.S. Charney, J.T. Coyle, C. Nemeroff (Eds.).
35. Lader M., Morton S. Benzodiazepine problems. Br J Addict 1991, 86:823-828.
36. Lau T., Schloss P. The cannabinoid CB1 receptor is expressed on serotonergic and dopaminergic neurons. Eur J Pharmacol 2008, 578:137-141.
37. Leonhardt V., Leal-Cardoso J.H., Lahlou S., Albuquerque A.A.C., Porto R.S., CeledÔnio N.R., et al. Antispasmodic effects of essential oil of Pterodon polygalaeflorus and its main constituent β-caryophyllene on rat isolated ileum. Fundam Clin Pharmacol 2010, 24:749-758.
38. Lepicard E.M., Joubert C., Hagneau I., Perez-Diaz F., Chapouthier G. Differences in anxiety-related behavior and response to diazepam in BALB/cByJ and C57BL/6J strains of mice. Pharmacol Biochem Behav 2000, 67:739-748.
39. Lilly S.M., Tietz E.I. Chronic cocaine differentially affects diazepam's anxiolytic and anticonvulsant actions. Relationship to GABA(A) receptor subunit expression. Brain Res 2000, 882:139-148.
40. Lister R.G. The use of a plus maze to measure anxiety in the mouse. Psychopharmacology 1987, 92:180-185.
41. Malone M.H. Pharmacological approaches to natural product, screening and evaluation. New natural products and plant drugs with pharmacological, biological or therapeutical activity 1977, 24-53. Springer-Verlag, Berlin. H. Wagner, P. Wolf (Eds.).
42. Marco E.M., García-Gutiérrez M.S., Bermúdez-Silva F.J., Moreira F.A., Guimarães F., Manzanares J., et al. Endocannabinoid system and psychiatry: in search of a neurobiological basis for detrimental and potential therapeutic effects. Front Behav Neurosci 2011, 5:1-23.
43. Matos L.G., Santos L.D.A.R., Vilela C.F., Pontes I.S., Trevenzol L.M.F., Paula J.R., et al. Atividade analgésica e/ou antiinflamatória da fração aquosa do extrato etanólico das folhas da Spiranthera odoratissima A. St. Hillaire (manacá). Rev Bras Farmacognosia 2003, 3:15-16.
44. Matos L.G., Pontes I.S., Trevenzol L.M.F., Paula J.R., Costa E.A. Analgesic and anti-inflammatory activity of the ethanolic extract from Spiranthera odoratissima A. St. Hillaire (manacá) roots. Phytother Res 2004, 18:963-966.
45. Matos L.G., Galdino P.M., Maldaner R.R., Costa E.A., Paula J.R. Estudo das atividades no sistema nervoso central da fração hexânica do extrato etanólico das folhas da Spiranthera odoratissima. Anais do XIX Simpósio de Plantas Medicinais do Brasil, Salvador-BA 2006.
46. Matsuda L.A., Lolait S.J., Brownstein M.J., Young A.C., Bonner T.I. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990, 346:561-564.
47. McLaughlin R.J., Hill M.N., Gorzalka B.B. Monoaminergic neurotransmission contributes to cannabinoid-induced activation of the hypothalamic-pituitary-adrenal axis. Eur J Pharmacol 2009, 624:71-76.
48. Medeiros R., Passos G.F., Vitor C.E., Koepp J., Mazzuco T.L., Pianowski L.F., et al. Effect of two active compounds obtained from the essential oil of Cordia verbenacea on the acute inflammatory responses elicited by LPS in the rat paw. Br J Pharmacol 2007, 151:618-627.
49. Molina-Hernández M., Tellez-Alcántara N.P., García J.P., Lopez J.I.O., Jaramillo M.T. Anxiolytic-like actions of leaves of Casimiroa edulis (Rutaceae) in male Wistar rats. J Ethnopharmacol 2004, 93:93-98.
50. Molina-Jasso D., Álvarez-González I., Madrigal-Bujaidar E. Clastogenicity of beta-caryophyllene in mouse. Biol Pharm Bull 2009, 32:520-522.
51. Mora S., Diaz-Veliz G., Lungenstrass H., García-González M., Coto-Morales T., Poletti C., et al. Central nervous system activity of the hydroalcoholic extract of Casimiroa edulis in rats and mice. J Ethnopharmacol 2005, 97:191-197.
52. Morgan N.H., Stanford I.M., Woodhall G.L. Functional CB2 type cannabinoid receptors at CNS synapses. Neuropharmacology 2009, 57:356-368.
53. Munro S., Thomas K.L., Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993, 365:61-65.
54. Novas M.L., Wolfman C., Medina J.H., De Robertis E. Proconvulsant and anxiogenic effects of n-butyl-β-carboline-3-carboxilate on endogenous benzodiazepine binding inhibitor from brain. Pharmacol Biochem Behav 1988, 30:331-336.
55. Onaivi E.S., Ishiguro H., Gong J.P., Patel S., Perchuk A., Meozzi P.A., et al. Discovery of the presence and functional expression of cannabinoid CB2 receptors in brain. Ann N Y Acad Sci 2006, 1074:514-536.
56. Passos G.F., Fernandes E.S., Cunha F.M., Ferreira J., Pianowski L.F., Campos M.M., et al. Anti-inflammatory and anti-allergic properties of the essential oil and active compounds from Cordia verbenacea. J Ethnopharmacol 2006, 110:323-333.
57. Pellow S., Chopin P., File S., Briley M. Validation of open-closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J Neurosci Methods 1985, 14:149-167.
58. Prut L., Belzung C. The open field as a paradigm to measure the effects of drugs on anxiety-like behaviors: a review. Eur J Pharmacol 2003, 463:3-33.
59. 1A receptor: G protein coupling and signaling pathways. Br J Pharmacol 1999, 127:1751-1764.
60. Rodgers R.J., Cole J.C. The elevated plus-maze: pharmacology, methodology and ethology. Ethology and psychopharmacology 1994, 9-44. Wiley, Chichester. S.J. Cooper, C.A. Hendrie (Eds.).
61. Salles A.H., Reis G.M.C.L., Zurlo M.A. Horto Medicinal do Cerrado 1997, Jardim Botânico de Brasília, Brasilia.
62. Savić M.M., Obradović D.I., Ugresić N.D., Cook J.M., Yin W., Bokonjić D.R. Bidirectional effects of benzodiazepine binding site ligands in the elevated plus-maze: differential antagonism by flumazenil and beta-CCt. Pharmacol Biochem Behav 2004, 79:279-290.
63. Siegel P.S. A simple electronic device for the measurement of gross bodily activity of small animals. J Psychol 1946, 21:227-236.
64. Siemiatkowski M., Sienkiewicz-Jarosz H., Czlonkowska A.I., Bidzinski A., Plaznik A. Effects of buspirone, diazepam, and zolpidem on open field behavior, and brain [3H]muscimol binding after buspirone pretreatment. Pharmacol Biochem Behav 2000, 66:645-651.
65. Silva S.R. Plantas do cerrado 1998, FUNATURA, Brasília.
66. Sousa F.C.F., Melo C.T.V., Citó M.C.O., Félix F.H.C., Vasconcelos S.M.M., Fonteles M.M.F., et al. Plantas medicinais e seus constituintes bioativos: Uma revisão da bioatividade e potenciais benefícios nos distúrbios da ansiedade em modelos animais. Rev Bras Farmacognosia 2008, 18:642-654.
67. Standen M.D., Connellan P.A., Leach D.N. Natural killer cell activity and lymphocyte activation: investigating the effects of a selection of essential oils and components in vitro. Int J Aromather 2006, 16:133-139.
68. Stefanski R., Pałejko W., Kostowski W., Płaznik A. The comparison of benzodiazepine derivates and serotonergic agonists and antagonists in two animal models of anxiety. Neuropharmacology 1992, 31:1251-1258.
69. Takeda H., Tsuji M., Matsumiya T. Changes in head-dipping behavior in the hole-board test reflect the anxiogenic and/or anxiolytic state in mice. Eur J Pharmacol 1998, 350:21-29.
70. Tambe Y., Tsujiuchi H., Honda G., Ikeshiro Y., Tanaka S. Gastric cytoprotectio of the non-steroidal anti-inflammatory sesquiterpene, beta-caryophyllene. Planta Med 1996, 5:469-470.
71. Tresvenzol L.M., Paula J.R., Ricardo A.F., Ferreira H.D., Zatta D.T. Estudo sobre o comércio informal de plantas medicinais em Goiânia e cidades vizinhas. Rev EletrÔnica da Farmácia 2006, 3:23-28.